Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

RiVax receives FDA orphan drug status for prevention of ricin intoxication

Jan. 24, 2011

Histamine H3 receptor antagonist JNJ-39220675 shows promise against alcoholism

Jan. 21, 2011

FDA approves new formulation of acetylcysteine injection

Jan. 18, 2011

New cannabinoid CB1 receptor antagonists presented by sanofi-aventis

Jan. 13, 2011

Anticocaine vaccine dAd5GNC shows promise in mice

Jan. 11, 2011

Lundbeck completes two phase III trials of nalmefene for alcohol dependence

Jan. 3, 2011

Preliminary phase Ib/IIa data presented on ibudilast in opioid addiction

Dec. 15, 2010

Orexo's new sublingual tablet formulation of buprenorphine/naloxone completes phase I trial

Dec. 15, 2010

Aoxing Pharma begins trial of sublingual buprenorphine/naloxone for opioid addiction

Dec. 13, 2010

Alkermes presents phase II data on ALKS-33 in alcohol dependence

Dec. 10, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...